Cronos Q3 revenue surges 75% on cannabis flower sales in Israel, Germany
Cronos reports strong third-quarter growth driven by flower demand in two key European and Middle Eastern markets.
FILE — harvest · My 420 Tours / CC BY-SA 4.0Cronos Group posted a 75% revenue increase in the third quarter, citing cannabis flower demand in Israel and Germany as primary drivers, according to TradingView. The result suggests the company is capitalizing on expanding medical access in both jurisdictions, where regulatory momentum has shifted markedly in recent months.
Israel's market backdrop includes advancing decriminalization efforts and a Knesset legalization bill in its first reading as of late July, alongside ongoing Health Ministry updates to prescription guidelines. Germany continues as a established medical cannabis market. The outsized growth underscores flower's continued commercial relevance despite earlier Israeli debates over its medical role.
Watch for Cronos's forward guidance and whether the flower-driven momentum sustains as Israel's legislative process advances and competitive pressures—including anti-dumping scrutiny on Canadian imports—intensify.
Original report: TradingView ↗